Table I.
Changes in the serum levels of tumor markers during chemotherapy.
| Tumor markers | ||||
|---|---|---|---|---|
| Chemotherapy cycle | CEA (ng/ml) | CA 15-3 (U/ml) | CYRA21-1 (ng/ml) | NSE (ng/ml) |
| Baseline | >1,000.0 | 159.7 | 165.0 | 35.6 |
| Second | >1,000.0 | 121.8 | 6.5 | 24.0 |
| Third | >1,000.0 | 97.9 | 5.5 | 15.0 |
| Fourth | >1,000.0 | 74.7 | 3.6 | 12.1 |
| Fifth | 941.6 | 50.0 | 2.8 | 9.5 |
| Sixth | 747.5 | 48.0 | 2.5 | 10.1 |
| Seventh | 721.8 | 43.4 | 1.6 | 10.2 |
| Eighth | 395.3 | 41.8 | 1.2 | 10.0 |
Tumor markers were measured prior to each chemotherapy cycle. Data are presented as single measurements. CEA, carcinoembryonic antigen; CA 15-3, carcinoma antigen 15-3; NSE, neuron-specific enolase.